Skip to content

Axogen AXGN Stock-Based Comp

Stock-Based Comp at other companies

Baxter International logo
Baxter InternationalBAX
$10M0.0%
Stryker logo
StrykerSYK
$87M+3.6%
LeMaitre Vascular logo
LeMaitre VascularLMAT
$2.09M+2.2%
Medtronic logo
MedtronicMDT
$95M+6.7%

Other financials

Income statement

See full
Revenue$61.5M+26.6%
Gross profit$46.2M+32.2%
Operating income-$2.8M-70.5%
Net income-$19.6M-411%
EPS (diluted)-$0.38-375%

Balance sheet

See full
Cash & equivalents$84.7M+251%
Total debt$20.6M-69.8%
Total equity$244.8M+132%
Total assets$289.5M+47.6%

Cash flow

See full
Operating cash flow$1.6M+112%
CapEx$2.8M+989%
Free cash flow-$1.2M+90.9%

Valuation

See full
Market cap$2.26B+110%

Profitability

See full
Gross margin75%+0.8pp
Operating margin-3.8%
Net margin-13.2%-22.8pp
FCF margin-12.9%-3.8pp

Returns & leverage

See full
Return on equity-18%-70.5pp
Debt / equity0.1×-0.6×
Current ratio7.1×+2.8×

Where this comes from

Reported directly by Axogen in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: Axogen’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about Axogen's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Axogen's stock-based comp?
Axogen (AXGN) reported stock-based comp of $6.84M in Q1 2026.
How has Axogen's stock-based comp changed year-over-year?
Axogen's stock-based comp increased by 135.2% year-over-year, from $2.91M to $6.84M.
What is the long-term trend for Axogen's stock-based comp?
Over 4 years (2021 to 2025), Axogen's stock-based comp has grown at a 28.9% compound annual growth rate (CAGR), from $10.92M to $30.11M.
What does stock-based comp mean?
Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.